Currently out of the existing stock ratings of Jason Kolbert, 586 are a BUY (96.7%), 20 are a HOLD (3.3%).

Jason Kolbert

Work Performance Price Targets & Ratings Chart

Analyst Jason Kolbert, currently employed at D. BORAL CAPITAL, carries an average stock price target met ratio of 45.1% that have a potential upside of 63.85% achieved within 395 days. Previously, Jason Kolbert worked at DAWSON JAMES.

Jason Kolbert’s has documented 1,043 price targets and ratings displayed on 91 stocks. The coverage is on Healthcare, Technology sectors.

Most recent stock forecast was given on ANIX, Anixa Biosciences at 30-Jun-2026.

Wall Street Analyst Jason Kolbert

Analyst best performing recommendations are on VNRX (VOLITIONRX LTD).
The best stock recommendation documented was for IVVD (INVIVYD) at 8/25/2025. The price target of $1 was fulfilled within 1 day with a profit of $0.44 (78.57%) receiving and performance score of 785.71.

Average potential price target upside

of $2288.4 (42.82%) on AEZS (AETERNA ZENTARIS).
of $1033.2 (99.96%) on GLMD (GALMED PHARMACEUTICALS LTD).
of $142.29 (96.8%) on ADMP (ADAMIS PHARMA).

ADMP Adamis Pharma AEZS Aeterna Zentaris ATHX Athersys BCLI Brainstorm Cell Therapeutics BLRX BioLineRx Ltd CTXR Citius Pharmaceuticals FBIO Fortress Biotech GILD Gilead Sciences GLMD Galmed Pharmaceuticals Ltd INO Inovio Pharmaceuticals ISR IsoRay MESO Mesoblast Ltd MNKD MannKind Corp NTEC Intec Pharma Ltd OMER Omeros PSTI Pluristem SRNE Sorrento Therape ACHN Achillion Pharmaceuticals CLBS Caladrius Biosciences TEVA Teva Pharma Industries Ltd ADR VRTX Vertex Pharmaceuticals AVXL Anavex Life Sciences Corp PSTV Plus Therapeutics PRPH ProPhase Labs BCDA Biocardia ADMA ADMA Biologics BGNE BeiGene Ltd CFRX ContraFect Corp CHEK Check Cap Ltd SNGX Soligenix CANF Can Fite Biopharma Ltd ADR ONCS OncoSec Medical DYAI Dyadic International ABUS Arbutus Biopharma Corp CHRS Coherus BioSciences CTSO Cytosorbents Crp DARE Dare Bioscience ANVS Annovis Bio ARTL Artelo Biosciences BMEA Biomea Fusion IBRX Immunitybio CLNN Clene CMPX Compass Therapeutics CRMD CorMedix ENLV Enlivex Therapeutics Ltd GOVX GeoVax Labs HOTH Hoth Therapeutics HUMA Humacyte IMUX Immunic IVVD Invivyd NRXP NRX Pharmaceuticals RCEL Avita Medical Ltd RVPH Reviva Pharmaceuticals Holdings TRVI Trevi Therapeutics URGN UroGen Pharma Ltd BJDX Bluejay Diagnostics CLGN Collplant Biotechnologies Ltd COYA Coya Therapeutics, Common Stock CRVO CervoMed MNOV MediciNova SNOA Sonoma Pharmaceuticals FBLG FibroBiologics, Common Stock BNTC Benitec Biopharma Ltd ADR CKPT Checkpoint Therapeutics CNTX Context Therapeutics IMAC Imac Holdings INDP Indaptus Therapeutics MBOT Microbot Medical NBY NovaBay Pharmaceuticals LUNG Pulmonx Corp VERI Veritone CODX Co-Diagnostics SINT SINTX Technologies SPHS Sophiris Bio XAIR Beyond Air NRSN AREC American Resources Corp EVTL Vertical Aerospace Ltd MVIS Microvision AGEN Agenus ANIX Anixa Biosciences KTRA Kintara Therapeutics LCTX Lineage Cell Therapeutics MNTA Momenta Pharmaceuticals NNOX Nano X Imaging Ltd SCLX Scilex Holding Company SGLB Sigma Labs STEM Stem BEAT Heartbeam CETX VNRX Volitionrx Ltd

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Jason Kolbert (D. BORAL CAPITAL)

Hold Since 22-Mar-2022

Please subscribe to see extended stock data

Jason Mccarthy (MAXIM GROUP)

Hold Since 16-Nov-2020

$1.5

Please subscribe to see extended stock data

Elliot Wilbur

Hold Since 26-Nov-2019

Please subscribe to see extended stock data

Greg Chodaczek

Please subscribe to see extended stock data

Show more analysts

Please expand the browser size to see the chart

Which stock is Jason Kolbert is most bullish on?

Potential upside of $30.44 has been obtained for NRXP (NRX PHARMACEUTICALS)

Which stock is Jason Kolbert is most reserved on?

Potential downside of -$13.86 has been obtained for URGN (UROGEN PHARMA LTD)

What Year was the first public recommendation made by Jason Kolbert?

On 2012